seliciclib

Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50=0.1 µM). Seliciclib also inhibits Cdk7/cyclin H, Cdk5/p35 and Cdc2/cyclin B (IC50=0.49/0.16/0.65 µM). Seliciclib has antitumor activity.

(Rac)-Roscovitine ((Rac)-Seliciclib) is a selective inhibitor of cyclin-dependent kinases (CDKs). It competes with ATP for binding at the active site of CDKs, thereby inhibiting their phosphorylation activity. This compound induces apoptosis in cancer cells and holds potential for the study of conditions like cancer, neurodegenerative diseases, heart diseases, viral and protozoal infections, glomerulonephritis, and chronic inflammation, all of which are associated with CDK dysregulation.

(S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent inhibitor of CDKs capable of crossing the blood-brain barrier. It exhibits neuroprotective effects and holds potential for use in stroke research.